Basilea Pharmaceutica AG (BPMUF)

Market Cap	922.35M +75.2%
Revenue (ttm)	297.01M +58.5%
Net Income	91.36M
EPS	6.88
Shares Out	n/a
PE Ratio	10.10
Forward PE	13.25
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	60
Open	71.00
Previous Close	71.60
Day's Range	71.00 - 71.00
52-Week Range	47.50 - 74.00
Beta	0.45
RSI	62.53
Earnings Date	Feb 17, 2026

About Basilea Pharmaceutica AG

Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), and acute bacterial skin and skin structure infections (ABSSSI). The company also has a clinical-stage pipeline of anti-infectiv...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 180
• Stock Exchange: OTCMKTS
• Ticker Symbol: BPMUF

Financial Performance

In 2024, Basilea Pharmaceutica AG's revenue was 208.54 million, an increase of 32.30% compared to the previous year's 157.63 million. Earnings were 77.59 million, an increase of 642.45%.

Financial numbers in CHF